Literature DB >> 22328953

Osseous metastasis of cutaneous squamous cell carcinoma treated successfully with oxaliplatin, tegafur and leucovorin combination chemotherapy: a case report.

Hong-Wei Xu1, Feng Ren, Wei Chen, Ying-Jie Wang, Jin Chen, Zhi-Hui Xie, Jin-Hu Yang, Jian-Jun Chu, Xu-Yang You.   

Abstract

Bone metastasis from cutaneous squamous cell carcinoma (SCC) is rare. We report a case of cutaneous SCC which was diagnosed by the presence of bone metastasis and treated with combination chemotherapy. A 53 year male had tissue contusion and persistent ulcer in the multiple regions of body for about 30 years and treat with Chinese Herbal Drugs in several hospitals, however, did not thorough cure. He was referred to our hospital for a dermatological examination in March 2009. Excisional biopsy and positron emission tomography-computed tomography (PET-CT) scan showed an invasive cutaneous SCC concomitant bone metastasis. Surgical treatment is limited, because of multiple cancerous ulcer and metastatic spreading. Therefore, we proceed to treat with oxaliplatin, tegafur and leucovorin (LV) combination chemotherapy and other adjuvant therapy. About 5 months following chemotherapy, the general situation of the patient was improved. Further cycle of chemotherapy resulted in complete disappearance of the tumor masses (confirmed by PET-CT). So far, there was no evidence of local recurrence or distant metastasis. This report indicates that the combination chemotherapy of oxaliplatin, tegafur and LV seems to have a considerable therapeutic effect for cutaneous SCC concomitant malignant bone metastasis.

Entities:  

Keywords:  Cutaneous squamous cell carcinoma; PET-CT; bone metastasis; chemotherapy

Year:  2012        PMID: 22328953      PMCID: PMC3272691     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  Cutaneous squamous-cell carcinoma.

Authors:  M Alam; D Ratner
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

2.  Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial.

Authors:  Luke Rudmik; Harold Y Lau; T Wayne Matthews; J Douglas Bosch; Reinhard Kloiber; Christine P Molnar; Joseph C Dort
Journal:  Head Neck       Date:  2010-11-12       Impact factor: 3.147

3.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.

Authors:  O Rixe; W Ortuzar; M Alvarez; R Parker; E Reed; K Paull; T Fojo
Journal:  Biochem Pharmacol       Date:  1996-12-24       Impact factor: 5.858

4.  Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer.

Authors:  Jill Gilbert; Barbara Murphy; Mary S Dietrich; Eve Henry; Richard Jordan; Ashley Counsell; Pamela Wirth; Wendell G Yarbrough; Robert J Slebos; Christine H Chung
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

Review 5.  Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients.

Authors:  James Leroy Wells; Keisuke Shirai
Journal:  Am J Clin Oncol       Date:  2012-10       Impact factor: 2.339

6.  Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer.

Authors:  Katie L Newbold; Mike Partridge; Gary Cook; Bhupinder Sharma; Peter Rhys-Evans; Kevin J Harrington; Christopher M Nutting
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

7.  Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.

Authors:  James Carmichael; Tadeusz Popiela; David Radstone; Stephen Falk; Markus Borner; Amit Oza; Torben Skovsgaard; Stephane Munier; Christophe Martin
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

8.  Intramuscular metastasis of cutaneous squamous cell carcinoma: a case report.

Authors:  Yu-Li Yang; Chung-Sheng Lai; Sin-Daw Lin; Chien-Kuo Wang; Kun-Bow Tsai
Journal:  Kaohsiung J Med Sci       Date:  2003-04       Impact factor: 2.744

9.  'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.

Authors:  J Bennouna; H Perrier; B Paillot; F Priou; J H Jacob; M Hebbar; S Bordenave; J F Seitz; F Cvitkovic; E Dorval; K Malek; D Tonelli; J Y Douillard
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

10.  Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer.

Authors:  H Y Sheikh; J W Valle; T Waddell; K Palmer; G Wilson; A Sjursen; O Craven; R Swindell; M P Saunders
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

  10 in total
  2 in total

1.  Diagnostic role of (99)Tc(m)-MDP SPECT/CT combined SPECT/MRI Multi modality imaging for early and atypical bone metastases.

Authors:  Xiao-Liang Chen; Qian Li; Lin Cao; Shi-Xi Jiang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Intra-arterial intervention chemotherapy for sarcoma and cancerous ulcer via an implanted pump.

Authors:  Cheng Liu; Qiu Cui; Jun Guo; Dingfeng Li; Yanjun Zeng
Journal:  Pathol Oncol Res       Date:  2014-01-21       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.